Alivus Life Sciences Ltd approves Q2 FY27 results, with net profit up 51.3% YoY to ₹196.7 crore
- Revenue was ₹682.0 crore, up 16.0% YoY and 6.5% sequentially.
- Operating margin rose to 35.7%, from 27.3% in Q2 FY26 and 29.8% in Q1 FY27.
- No exceptional items were reported; statutory auditor issued an unmodified limited-review conclusion.